KYTX Filings — Kyverna Therapeutics, Inc. - FilingSpy
KYTX
Kyverna Therapeutics, Inc.
A clinical-stage biotech company engineering patients' own immune cells to fight autoimmune diseases such as lupus. Kyverna's lead therapy, KYV-101, is a CAR T-cell treatment that reprograms a patient's T cells to seek out and quiet the rogue immune cells driving the disease. Founded in 2018 in the San Francisco Bay Area, the company takes its name from the Greek word for "govern" or "guide," reflecting its aim to steer the immune system back into balance.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +242.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.